Reaction Details |
| Report a problem with these data |
Target | Vasopressin V1b receptor |
---|
Ligand | BDBM86209 |
---|
Substrate/Competitor | n/a |
---|
Ki | 657±n/a nM |
---|
Comments | PDSP_6851 |
---|
Citation | Cirillo, R; Gillio Tos, E; Schwarz, MK; Quattropani, A; Scheer, A; Missotten, M; Dorbais, J; Nichols, A; Borrelli, F; Giachetti, C; Golzio, L; Marinelli, P; Thomas, RJ; Chevillard, C; Laurent, F; Portet, K; Barberis, C; Chollet, A Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. J Pharmacol Exp Ther306:253-61 (2003) [PubMed] Article |
---|
More Info.: | Get all data from this article |
---|
|
Vasopressin V1b receptor |
---|
Name: | Vasopressin V1b receptor |
Synonyms: | AVPR V1b | AVPR V3 | AVPR1B | AVPR3 | Antidiuretic hormone receptor 1b | V1BR_HUMAN | V1bR | VASOPRESSIN V1B | VPR3 | Vasopressin V1b receptor | Vasopressin V1b receptor (V1b) | Vasopressin V3 | Vasopressin V3 receptor |
Type: | Enzyme |
Mol. Mass.: | 46985.01 |
Organism: | Homo sapiens (Human) |
Description: | P47901 |
Residue: | 424 |
Sequence: | MDSGPLWDANPTPRGTLSAPNATTPWLGRDEELAKVEIGVLATVLVLATGGNLAVLLTLG
QLGRKRSRMHLFVLHLALTDLAVALFQVLPQLLWDITYRFQGPDLLCRAVKYLQVLSMFA
STYMLLAMTLDRYLAVCHPLRSLQQPGQSTYLLIAAPWLLAAIFSLPQVFIFSLREVIQG
SGVLDCWADFGFPWGPRAYLTWTTLAIFVLPVTMLTACYSLICHEICKNLKVKTQAWRVG
GGGWRTWDRPSPSTLAATTRGLPSRVSSINTISRAKIRTVKMTFVIVLAYIACWAPFFSV
QMWSVWDKNAPDEDSTNVAFTISMLLGNLNSCCNPWIYMGFNSHLLPRPLRHLACCGGPQ
PRMRRRLSDGSLSSRHTTLLTRSSCPATLSLSLSLTLSGRPRPEESPRDLELADGEGTAE
TIIF
|
|
|
BDBM86209 |
---|
n/a |
---|
Name | BDBM86209 |
Synonyms: | Atosiban | CAS_90779-69-4 | NSC_0 |
Type | Small organic molecule |
Emp. Form. | C43H67N11O12S2 |
Mol. Mass. | 994.189 |
SMILES | CCOc1ccc(CC2NC(=O)CCSSCC(NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(NC2=O)C(C)CC)C(C)O)C(=O)N2CCCC2C(=O)NC(CCCN)C(=O)NCC(N)=O)cc1 |
Structure |
|